Cardiovascular effects of intravenous vatinoxan in wild boars (Sus scrofa) anaesthetised with intramuscular medetomidine-tiletamine-zolazepam.

Abstract

The potent sedative medetomidine is a commonly used adjunct for the immobilisation of non-domestic mammals. However, its use is associated with pronounced cardiovascular side effects, such as bradycardia, vasoconstriction and decreased cardiac output. We investigated the effects of the peripherally-acting alpha-2-adrenoceptor antagonist vatinoxan on cardiovascular properties in medetomidine-tiletamine-zolazepam anaesthetised wild boar (Sus scrofa). Twelve wild boars, anaesthetised twice with medetomidine (0.1mg/kg) and tiletamine/zolazepam (2.5mg/kg) IM in a randomised, crossover study, were administered (0.1mg/kg) vatinoxan or an equivalent volume of saline IV (control). Cardiovascular variables, including heart rate (HR), mean arterial blood pressure (MAP), pulmonary artery pressure (PAP), pulmonary artery occlusion pressure (PAOP) and cardiac output (CO), were assessed 5 min prior to vatinoxan/saline administration until the end of anaesthesia 30 min later. MAP (p<0.0001), MPAP (p<0.001) and MPAOP (p<0.0001) significantly decreased from baseline after vatinoxan until the end of anaesthesia. HR increased significantly (p<0.0001) from baseline after vatinoxan administration. However, the effect on HR subsided 3 min after vatinoxan. All variables remained constant after saline injection. There was no significant effect of vatinoxan or saline on CO. Vatinoxan significantly reduced systemic and pulmonary artery hypertension, induced by medetomidine in wild boar.